Tag: Doac

Cardioembolism, often from atrial fibrillation (AFib), accounts for about 20% of all ischemic strokes. For these patients, a critical question is 'What is the 1 2 3 4 rule for anticoagulation stroke?' This framework guides treatment timing to prevent recurrence while minimizing risk.

The annual risk of major bleeding for patients using oral anticoagulants ranges from 2% to 5% [1.2.2]. The critical question, 'Does anticoagulant cause bleeding?', is best answered by understanding that bleeding is not just a side effect, but an extension of the medication's intended purpose [1.2.2, 1.3.3].

According to the CDC, anticoagulant use is a leading cause of adverse drug event-related hospitalizations in older adults, making the choice of medication critical. While both Xarelto and Eliquis are popular blood thinners, **are Xarelto and Eliquis the same**? They are not, and understanding their distinct profiles is essential for making informed treatment decisions.

According to observational studies, discontinuing anticoagulation after a major bleed significantly increases the risk of thromboembolic events and death, yet restarting too early risks re-bleeding. Determining *when to restart anticoagulation after hemorrhage* is a nuanced balancing act between competing risks.

Ischemic strokes account for about 85% of all strokes. Following a mechanical thrombectomy to remove a blood clot, a critical question arises for clinicians: when to start anticoagulation after thrombectomy to prevent another stroke without causing dangerous bleeding?

In June 2020, Portola Pharmaceuticals conducted a market withdrawal of Betrixaban (Bevyxxa) for business reasons, not due to specific safety or quality concerns. This article explores the clinical trial data, market challenges, and regulatory hurdles that answer the question: **Why was Betrixaban discontinued?**

From 2011 to 2020, the use of direct oral anticoagulants (DOACs) like Eliquis rose from 4.7% to 47.9% among at-risk atrial fibrillation patients [1.5.1]. If you're wondering 'What can you substitute Eliquis with?', it's crucial to understand the approved medical alternatives.

Over the last decade, non-vitamin K oral anticoagulants (NOACs), also known as direct oral anticoagulants (DOACs), have increasingly replaced warfarin for many indications, offering a more convenient and often safer treatment for patients. These agents were developed to overcome the limitations of older anticoagulants, providing a more predictable and streamlined therapy.

As of 2020, over 7.6 million non-institutionalized adults in the U.S. use oral anticoagulants [1.8.1]. If you are one of them, it is crucial to understand, 'What should I watch while on blood thinners?' to minimize risks and ensure your medication works effectively.